Senate Republicans released their version of the Trump administration’s “One Big Beautiful Bill Act” on Monday with a few ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s ...

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

The biopharma industry has hit a setback in its ambition to leverage President Donald Trump’s “big, beautiful bill” to amend ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

CERo Therapeutics Holdings Inc (NASDAQ:CERO) shares are trading higher Tuesday after the company received U.S. Food and Drug ...

A controversial proposal to change the Inflation Reduction Act’s pricing framework for rare disease drugs has been dropped ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

Capricor Therapeutics has received an orphan drug designation for its drug aimed at potentially treating Becker Muscular Dystrophy. The biotechnology company said Tuesday that the Food and Drug ...

Investing.com -- CERo Therapeutics Holdings Inc (NASDAQ: CERO) stock surged 191.6% after the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for the company’s lead drug ...